Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.
about
Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4Benzodiazepine Use During Hospitalization: Automated Identification of Potential Medication Errors and Systematic Assessment of Preventable Adverse EventsAn S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator.Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess.Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungalsRitonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo.Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies.Dealing with the complex drug-drug interactions: towards mechanistic models.Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies.Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation.Prediction of drug-drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition.Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat.Use of a semi-physiological pharmacokinetic model to investigate the influence of itraconazole on tacrolimus absorption, distribution and metabolism in mice.Syndrome of inappropriate antidiuretic hormone secretion from concomitant use of itraconazole and vindesine.Mechanisms and the clinical relevance of complex drug-drug interactionsPBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
P2860
Q28307990-7DB0DA06-5338-4A6C-B91A-35410F1A8EB2Q28554558-7E682B53-F707-4D32-9B6B-4278C279D36EQ31123470-1F568115-F29A-446F-9B14-7F6B2206EDF5Q33404180-17DA7408-F2CB-4201-A153-79D78540EF04Q35776638-D699112A-8297-4DD6-9325-1F258E7C7DF0Q36072448-8B4EC27F-A82D-45A7-AD6C-15456848C149Q36349377-4130B04B-BCF0-4C0B-90CB-7B2313AC46BBQ37325598-C1D728EB-190A-4A7F-981D-90F739F30E60Q37580873-596FA79C-1025-4F67-9D52-7BB7F09F56F5Q37945308-EDE02524-1A88-4894-9924-24B482A97611Q37989979-3179EB5A-3EDD-40DC-A421-6333FC3C97C3Q38205664-70820E9F-0930-4A53-A810-05EE9DED8BCCQ38302225-C3C167F0-87CE-4957-8044-07A54EC64D42Q38516237-A6420669-9415-4A9E-B230-721E53D3967EQ38726643-843229D0-59A2-4051-BB80-24E4F8C183CEQ38811728-3150FDD5-3397-4F5F-B2A7-EE38B5AC5350Q38958223-81C8C8F6-5895-4573-B70B-64CC4B2C00ADQ39194285-66829DC1-F512-48C7-A699-906D9D5E464FQ39952608-0A664AF6-F7DA-4B45-B472-F33BE0698939Q40183320-95779B9B-BD1C-49EC-BDE1-4EEEBA46F8AEQ41962845-81CEE26A-0D12-4918-883F-3179DC0CCD6AQ45160680-1FA95413-4A2B-4BCB-9789-CCDC694A2A62Q48566470-DE9712D8-A2D4-4C81-B9A4-1DEDE598B24AQ53123208-73986109-9784-42AC-AF9C-01F83BC96CC2Q57490721-F0C64026-8E0F-4E50-B241-B91160BEDA61Q58758044-1B342CFE-53BA-4538-B140-F75A079C9635
P2860
Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Accurate prediction of dose-de ...... from in vitro inhibition data.
@ast
Accurate prediction of dose-de ...... from in vitro inhibition data.
@en
type
label
Accurate prediction of dose-de ...... from in vitro inhibition data.
@ast
Accurate prediction of dose-de ...... from in vitro inhibition data.
@en
prefLabel
Accurate prediction of dose-de ...... from in vitro inhibition data.
@ast
Accurate prediction of dose-de ...... from in vitro inhibition data.
@en
P2093
P2860
P356
P1476
Accurate prediction of dose-de ...... from in vitro inhibition data.
@en
P2093
I Templeton
K E Thummel
N Isoherranen
P2860
P304
P356
10.1038/CLPT.2010.119
P407
P577
2010-08-25T00:00:00Z